A Field Study for the Evaluation of AIGIV Clinical Benefit and Safety in the Treatment of Patients With Inhalational Anthrax in a Broad Exposure Event Scenario
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Anthrax immune globulin (Primary)
- Indications Anthrax
- Focus Therapeutic Use
- Sponsors Emergent BioSolutions
- 14 Feb 2024 Planned End Date changed from 1 Jul 2025 to 1 Jul 2026.
- 14 Feb 2024 Planned primary completion date changed from 1 Jul 2025 to 1 Jul 2026.
- 14 Feb 2024 Planned initiation date changed from 11 Feb 2024 to 11 Feb 2025.